Integra LifeSciences Holdings Corporation
IART
$13.57
$0.564.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.62B | 1.61B | 1.56B | 1.57B | 1.53B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.62B | 1.61B | 1.56B | 1.57B | 1.53B |
| Cost of Revenue | 674.49M | 656.01M | 637.00M | 627.06M | 600.76M |
| Gross Profit | 949.81M | 954.52M | 927.92M | 939.44M | 928.84M |
| SG&A Expenses | 673.13M | 668.77M | 637.03M | 620.24M | 601.59M |
| Depreciation & Amortization | 14.89M | 14.23M | 13.54M | 12.99M | 12.31M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.46B | 1.43B | 1.38B | 1.35B | 1.30B |
| Operating Income | 168.10M | 177.12M | 189.02M | 220.96M | 231.49M |
| Income Before Tax | -43.04M | -18.24M | -11.92M | 27.05M | 46.06M |
| Income Tax Expenses | -14.09M | -11.29M | -5.38M | 3.40M | 5.83M |
| Earnings from Continuing Operations | -28.96 | -6.94 | -6.54 | 23.65 | 40.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.96M | -6.94M | -6.54M | 23.65M | 40.23M |
| EBIT | 168.10M | 177.12M | 189.02M | 220.96M | 231.49M |
| EBITDA | 315.61M | 318.02M | 316.21M | 356.94M | 354.42M |
| EPS Basic | -0.38 | -0.09 | -0.09 | 0.30 | 0.51 |
| Normalized Basic EPS | 0.95 | 1.06 | 1.20 | 1.47 | 1.57 |
| EPS Diluted | -0.38 | -0.09 | -0.09 | 0.29 | 0.50 |
| Normalized Diluted EPS | 0.95 | 1.06 | 1.20 | 1.47 | 1.57 |
| Average Basic Shares Outstanding | 306.74M | 308.01M | 309.55M | 312.79M | 316.35M |
| Average Diluted Shares Outstanding | 306.74M | 308.01M | 309.55M | 312.91M | 316.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |